Eli Lilly and Co (NYSE:LLY) SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Eli Lilly and Co (NYSE LLY) opened at $76.03 on Wednesday. The firm has a market cap of $83,870.00, a price-to-earnings ratio of -382.10, a PEG ratio of 1.42 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same period in the previous year, the company earned $0.95 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. analysts predict that Eli Lilly and Co will post 4.88 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.96%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is presently -1,040.00%.
A number of large investors have recently bought and sold shares of the business. Pathstone Family Office LLC raised its position in shares of Eli Lilly and by 100.0% during the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. acquired a new position in shares of Eli Lilly and during the 2nd quarter worth about $494,000. Gradient Investments LLC acquired a new position in shares of Eli Lilly and during the 4th quarter worth about $103,000. Acrospire Investment Management LLC raised its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new position in shares of Eli Lilly and during the 2nd quarter worth about $128,000. 76.20% of the stock is currently owned by institutional investors.
Several analysts have recently weighed in on the stock. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price target on shares of Eli Lilly and in a research note on Friday, February 2nd. Bank of America decreased their price target on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. BMO Capital Markets lifted their price target on shares of Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a research note on Thursday, February 1st. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $92.02.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/jeffrey-n-simmons-sells-9625-shares-of-eli-lilly-and-co-lly-stock.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.